S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(-0.08%) $0.926
USD/NOK
(-0.15%) $10.82
USD/GBP
(-0.09%) $0.792
USD/RUB
(-0.09%) $92.49

Realtime updates for Ensysce Biosciences, Inc. [ENSC]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 16:00

-2.44% $ 0.790

BUY 62919 min ago

@ $0.897

Issued: 14 Feb 2024 @ 15:28


Return: -11.86%


Previous signal: Feb 14 - 10:42


Previous signal: Sell


Return: -0.39 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States...

Stats
Today's Volume 122 822
Average Volume 1.53M
Market Cap 2.49M
EPS $0 ( 2024-03-19 )
Next earnings date ( $-0.860 ) 2024-04-04
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.170
ATR14 $0.0150 (1.91%)
Insider Trading
Date Person Action Amount type
2023-03-02 Gower Bob G Buy 90 287 Common Stock
2023-03-01 Gower Bob G Buy 270 000 Common Stock
2023-02-28 Gower Bob G Buy 109 300 Common Stock
2022-12-09 Gower Bob G Buy 357 143 Common Stock
2022-12-09 Gower Bob G Buy 714 286 Warrants
INSIDER POWER
96.87
Last 80 transactions
Buy: 23 095 136 | Sell: 3 675 006

Volume Correlation

Long: -0.27 (neutral)
Short: 0.61 (weak)
Signal:(51.381) Neutral

Ensysce Biosciences, Inc. Correlation

10 Most Positive Correlations
SVAC0.928
PAIC0.905
PRVB0.904
SVOK0.878
ALR0.862
TLGT0.852
ALLR0.847
LKCO0.844
RDHL0.843
ELEV0.839
10 Most Negative Correlations
NETE-0.92
LWAC-0.92
MDRRP-0.916
SRAC-0.904
WSBCP-0.895
RAVN-0.889
HNST-0.889
OVBC-0.886
MRBK-0.885
MNSBP-0.883

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ensysce Biosciences, Inc. Correlation - Currency/Commodity

The country flag -0.74
( moderate negative )
The country flag -0.63
( weak negative )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.51
( weak )

Ensysce Biosciences, Inc. Financials

Annual 2023
Revenue: $2.23M
Gross Profit: $2.23M (100.00 %)
EPS: $-4.69
Q4 2023
Revenue: $515 032
Gross Profit: $-2.92M (-567.87 %)
EPS: $-1.550
Q3 2023
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-0.870
Q2 2023
Revenue: $490 472
Gross Profit: $-1.15M (-235.13 %)
EPS: $-0.980

Financial Reports:

No articles found.

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators